{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:32Z","timestamp":1777564532825,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1888,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/jto.0b013e3181f209a8","type":"journal-article","created":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T11:29:35Z","timestamp":1285068575000},"page":"S286-S290","source":"Crossref","is-referenced-by-count":74,"special_numbering":"S4","title":["Thymoma and Thymic Carcinoma: Molecular Pathology and Targeted Therapy"],"prefix":"10.1016","volume":"5","author":[{"given":"Philipp","family":"Str\u00f6bel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hohenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181f209a8_bib1","series-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Thymus and Heart","first-page":"145","article-title":"Tumours of the thymus: Introduction","author":"M\u00fcller-Hermelink","year":"2004"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1196\/annals.1405.018","article-title":"Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms","volume":"1132","author":"Strobel","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/path.2141","article-title":"Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1)","volume":"211","author":"Strobel","year":"2007","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2249.2007.03442.x","article-title":"Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas","volume":"149","author":"Scarpino","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib5","first-page":"743","article-title":"Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas","volume":"78","author":"Nenninger","year":"1998","journal-title":"Lab Invest"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1365-2249.2000.01256.x","article-title":"Altered T cell development in human thymoma is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-gamma)","volume":"121","author":"Kadota","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib7","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/00000478-200212000-00008","article-title":"Correlation of the WHO schema for the classification of thymic epithelial neoplasms with prognosis: a retrospective study of 90 tumors","volume":"26","author":"Chalabreysse","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0344-0338(99)80006-5","article-title":"Thymic tumours in Denmark. A retrospective study of 213 cases from 1970\u20131993","volume":"195","author":"Engel","year":"1999","journal-title":"Pathol Res Pract"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00000478-200101000-00012","article-title":"Clinical and functional significance of WHO classification on human thymic epithelial neoplasms: a study of 146 consecutive tumors","volume":"25","author":"Okumura","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.athoracsur.2004.06.090","article-title":"Thymoma and myasthenia gravis: a clinical study of 1,089 patients from Japan","volume":"79","author":"Kondo","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib11","first-page":"3708","article-title":"Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas","volume":"63","author":"Inoue","year":"2003","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2559.1994.tb00594.x","article-title":"Evaluation of a histogenetic classification for thymic epithelial tumours","volume":"25","author":"Ho","year":"1994","journal-title":"Histopathology"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2004.10.113","article-title":"Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis","volume":"22","author":"Strobel","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.athoracsur.2009.08.074","article-title":"Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery","volume":"89","author":"Margaritora","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cncr.10665","article-title":"New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China","volume":"95","author":"Chen","year":"2002","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/1097-0142(19940715)74:2<606::AID-CNCR2820740212>3.0.CO;2-T","article-title":"Thymoma. Histologic subclassification is an independent prognostic factor","volume":"74","author":"Quintanilla-Martinez","year":"1994","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib17","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00432-004-0545-z","article-title":"Tyrosine kinase receptor expression in thymomas","volume":"130","author":"Henley","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib20","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1200\/JCO.2004.10.125","article-title":"Prevalence of KIT expression in human tumors","volume":"22","author":"Went","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0002-9440(10)64536-1","article-title":"Recurrent genetic aberrations in thymoma and thymic carcinoma","volume":"157","author":"Zettl","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib22","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib23","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0002-9440(10)64426-4","article-title":"Chromosome 6 suffers frequent and multiple aberrations in thymoma","volume":"161","author":"Inoue","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib24","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0002-9440(10)63031-3","article-title":"Thymic epithelial tumors can develop along two different pathogenetic pathways","volume":"159","author":"Zhou","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib25","series-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Thymus and Heart","first-page":"247","article-title":"Metastases to thymus and anterior mediastinum","author":"M\u00fcller-Hermelink","year":"2004"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3816\/CLC.2004.n.018","article-title":"Thymoma and thymic carcinoma: therapeutic approaches","volume":"6","author":"Kurup","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib27","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib28","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.seminoncol.2006.04.005","article-title":"New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors","volume":"33","author":"Faivre","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1470-2045(09)70017-8","article-title":"Emergency surgery in the era of molecular treatment of solid tumours","volume":"10","author":"Rutkowski","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib31","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Strobel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib32","first-page":"177","article-title":"[Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic perspective]","volume":"91","author":"Strobel","year":"2007","journal-title":"Verh Dtsch Ges Pathol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.lungcan.2008.03.035","article-title":"Absence of gene mutations in KIT-positive thymic epithelial tumors","volume":"62","author":"Tsuchida","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib34","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib35","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/MPH.0b013e318159a535","article-title":"Advanced pediatric inoperable thymus carcinoma (type C thymoma): case report on a novel therapeutic approach","volume":"29","author":"Kertesz","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"issue":"Suppl","key":"10.1097\/JTO.0b013e3181f209a8_bib36","article-title":"Imatinib for the treatment of thymic carcinoma","volume":"26","author":"Salter","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib37","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00432-001-0319-9","article-title":"Epidermal growth factor receptor expression in invasive thymoma","volume":"128","author":"Henley","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib39","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/cncr.20811","article-title":"Protein expression and gene amplification of epidermal growth factor receptor in thymomas","volume":"103","author":"Ionescu","year":"2005","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib40","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/annonc\/mdn388","article-title":"Response of malignant thymoma to erlotinib","volume":"19","author":"Christodoulou","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib41","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib42","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma","volume":"12","author":"Palmieri","year":"2007","journal-title":"Front Biosci"},{"issue":"Suppl","key":"10.1097\/JTO.0b013e3181f209a8_bib43","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1097\/JTO.0b013e3181f209a8_bib44","article-title":"Phase II study of gefitinib treatment in advanced thymic malignancies","volume":"23","author":"Kurup","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib45","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","volume":"407","author":"Adnane","year":"2006","journal-title":"Methods Enzymol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2009","journal-title":"Med Oncol"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib47","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib48","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience","volume":"103","author":"Strobel","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib49","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e3181f209a8_bib50","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415326186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415326186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T23:56:45Z","timestamp":1559692605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415326186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S1556086415326186"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181f209a8","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}